BioSpark

BioSpark is biotech/healthcare-focused Non-Profit Organization registered in the Massachusetts. Our events calendar:

[BioSpark @BioSpark_Group]

Is KRAS Finally Druggable? Pancreatic Cancer Breakthroughs on Daraxonras... https://t.co/sgl7VUsXqV via @YouTube

[BioSpark @BioSpark_Group]

Is KRAS Finally Druggable? Pancreatic Cancer Breakthroughs on Daraxonras... https://t.co/sgl7VUsXqV via @YouTube

[BioSpark @BioSpark_Group]

https://t.co/CTwKTxbgYL via @YouTube

[BioSpark @BioSpark_Group]

Join us on Saturday, May 30th, 2026, 9:00 PM EST for a live online webinar where we unpack the most exciting biotech breakthroughs from the past month!
https://t.co/LrYHG71Y9g via @YouTube

[BioSpark @BioSpark_Group]

Join us on Sat, Apr 25, 9:00 PM - 10:00 PM EDT for an expert-led deep dive into one of modern cancer research’s most transformative stories, as we chart KRAS’s journey from an untreatable target to a cornerstone of personalized cancer care.
https://t.co/M4dPplCYLV via @YouTube

[BioSpark @BioSpark_Group]

Merck’s HIF-2α Inhibitor: Analyzing the LITESPARK-012 Setback and the Fu... https://t.co/lZQ0OnfeNf via @YouTube

[BioSpark @BioSpark_Group]

https://t.co/stlK19wf5Q via @YouTube

[BioSpark @BioSpark_Group]

Join us on Saturday, May 2nd, 2026, 9:00 PM EST for a live online webinar where we unpack the most exciting biotech breakthroughs from the past month! Register Here: https://t.co/yJcvw6ZYUo

[BioSpark @BioSpark_Group]

The $1.1B Acquisition: Why UCB Just Bought Neurona Therapeutics (Feb 202... https://t.co/bJLKdmCuGk via @YouTube

[BioSpark @BioSpark_Group]

Join us on Sat, Apr 25, 9:00 PM - 10:00 PM EDT for an expert-led deep dive into one of modern cancer research’s most transformative stories, as we chart KRAS’s journey from an untreatable target to a cornerstone of personalized cancer care.
Register Here: https://t.co/4JxuOvy4OO

[BioSpark @BioSpark_Group]

【BioSpark Innovation Talk】Multimodal Mapping as a Foundation for Virtual... https://t.co/V1ACcwJT2z via @YouTube

[BioSpark @BioSpark_Group]

Xenon Pharmaceuticals' Azetukalner: Breakthrough Phase 3 Data in Epilepsy https://t.co/f8xJF66HKB via @YouTube

[BioSpark @BioSpark_Group]

CytomX Phase 1 Data: Is Varseta-M the Breakthrough Masked ADC for Colore... https://t.co/gZ2asZtTuV via @YouTube

[BioSpark @BioSpark_Group]

@AnAnnika32 @YouTube Glad to hear you found a path that works for you. It's exactly these life-changing potentials that make the latest Phase 3 clinical data so significant. Our session dives into the science and regulatory steps needed to make these therapies safe and accessible. Thanks for sharing!

[BioSpark @BioSpark_Group]

Compass Pathways Phase 3 Breakthrough: Synthetic Psilocybin for Treatmen... https://t.co/fAMKRC966Q via @YouTube

[BioSpark @BioSpark_Group]

The gap between molecular data and biological insight is closing. 🌉
Join us for BioSpark EP15 as Dr. Clara Hu reveals a new framework for the "Virtual Cell" powered by multimodal data & GPT-4.
📍 April 11, 9:00 PM EST Details below! 👇
https://t.co/nEIHJEvFd4 via @YouTube

[BioSpark @BioSpark_Group]

BioSpark Salon Recap: Biotech 2026 — Beyond the AI Hype & Capital Winter
https://t.co/P7PbEFvv2k

[BioSpark @BioSpark_Group]

https://t.co/0f6zRYQDU5 via @YouTube
Join us for our March 2026 Biotech News Review! 🚀 Don’t miss this live online seminar packed with expert insights on the latest biotech innovations! Register at https://t.co/rtBmIY4PFI

[BioSpark @BioSpark_Group]

I am hosting 【BioSpark Innovation Talk】AI Customization – Building Domain Intelligence for Life Sciences. Join me! https://t.co/8JoQjuQOdd via @LumaHQ

[BioSpark @BioSpark_Group]

Oral Macrocyclic Peptides: Merck’s Enlicitide Breakthrough & Novartis Deals https://t.co/JGbeLxjaK4 via @YouTube